SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 2
    Agarwala SS, Reyderman L, Statkevich P, et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma [abstract]. Ann Oncol. 1998; 9: 138.
  • 3
    Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin T, Decosterd LA. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 59a.
  • 4
    Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158166.
  • 5
    Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002; 12: 175178.
  • 6
    Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002; 8: 30753081.
  • 7
    Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 43634367.
  • 8
    Denis LJ, Tolcher A, Figueroa JA, et al. Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 202a.
  • 9
    Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 10041011.
  • 10
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91: 40824085.
  • 11
    Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996; 31: 213221.
  • 12
    Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998; 187: 18851892.
  • 13
    Fanelli M, Sarmiento R, Gattuso D, et al. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs. 2003; 12: 12111225.
  • 14
    Rajkumar SV. Current status of thalidomide in the treatment of cancer. Oncology (Huntingt). 2001; 15: 867874;discussion 877–879.
  • 15
    Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002; 20: 26102615.
  • 16
    Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003; 21: 33513356.
  • 17
    Hwu W-J, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001; 2: 634635.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 19
    Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004; 22: 12931300.
  • 20
    Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer. 1997; 76: 256259.
  • 21
    Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003; 26: 354357.
  • 22
    McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN. Treatment of brain metastases from melanoma. Mayo Clin Proc. 2003; 78: 15291536.
  • 23
    Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999; 43: 795803.
  • 24
    Proebstle TM, Fuchs T, Scheibenbogen C, Sterry W, Keilholz U. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res. 1998; 8: 557563.
  • 25
    Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci. 2000; 44: 211218; discussion 219.
  • 26
    Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004; 22: 610616.
  • 27
    Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004; 22: 21012107.
  • 28
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98: 16141615.
  • 29
    Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol. 2002; 20: 420425.
  • 30
    Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003; 21: 25512557.